Metastatic colorectal cancer: Updates in treatment strategies and what's in the works

Research output: Contribution to journalArticlepeer-review


Metastatic colorectal cancer (MCRC) management has improved significantly in the past decade. Several medications have been approved since the late 1990s, resulting in significant improvements in overall survival. Therapy continues to evolve with the discovery of various genetic differences which predict response to individual targeted agents.

Original languageEnglish (US)
Pages (from-to)33-36
Number of pages4
JournalJournal of Managed Care Medicine
Issue number3
StatePublished - Sep 16 2013


  • Biologics target key regulators of tumor cell growth, survival, metastasis, and angiogenesis
  • I mproved health outcomes can be achieved by using genetic mutation testing to avoid ineffective chemotherapy and potential side effects and expedite access to the most effective treatment
  • Metastatic colorectal cancer is still considered not curable
  • The presence of genetic mutations, including KRAS and BRAF mutations, can be used to guide biologic agent selection
  • Therapies approved in recent years have significantly improved median survival

ASJC Scopus subject areas

  • Health Policy


Dive into the research topics of 'Metastatic colorectal cancer: Updates in treatment strategies and what's in the works'. Together they form a unique fingerprint.

Cite this